T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for T CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new T CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for T CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Supercharged immune cells take on tough blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not responded to treatment. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from donated cord blood. The…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 20:47 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of immunotherapy called CAR T cells, made from a patient's own blood cells, to treat T-cell acute lymphoblastic leukemia and lymphoma that has relapsed or not responded to standard treatments. The CAR T cells are designed to target a p…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
Engineered immune cells take aim at tough T-Cell cancers
Disease control Recruiting nowThis early-phase trial tests a new approach for people with certain T-cell blood cancers (leukemia or lymphoma) that have returned. Researchers take a patient's own immune cells (or cells from a past stem cell donor), add a special receptor that targets a protein called CD5 found…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
New stem cell transplant method shows promise for kids with tough blood cancers
Disease control Recruiting nowThis study tests a new way to do stem cell transplants for children with blood cancers like leukemia. It uses a half-matched family donor and removes certain immune cells from the donated cells to lower risks. The goal is to see if this method is safe and helps the child's body a…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
Engineered immune cells take on relapsed leukemia in early trial
Disease control Recruiting nowThis study tests an experimental treatment called GYA01 (CART84) for adults with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab …
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Gyala Therapeutics • Aim: Disease control
Last updated Jun 22, 2026 12:06 UTC
-
Donor immune cells take on tough T-Cell cancers in new trial
Disease control Recruiting nowThis phase 2 trial tests a one-time infusion of WU-CART-007, a CAR-T cell therapy made from healthy donor cells, in 125 people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or not responded to treatment. The goal is to see if it can wipe ou…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
Cord blood cells engineered to fight Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new treatment using immune cells (NK cells) from donated cord blood that are engineered to target a protein called CD5 found on certain cancer cells. The treatment is given after chemotherapy to prepare the body, and the goal is to see if it is safe and effecti…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
New hope for tough leukemia cases: drug combo trial opens for kids and young adults
Disease control Recruiting nowThis study is for children, teens, and young adults (ages 1 to 39) with acute leukemia that has come back or not gotten better with standard treatments. Researchers are testing whether combining two drugs—venetoclax and Vyxeos—is safe and tolerable. The goal is to find the best d…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 22, 2026 11:54 UTC
-
New drug cocktail aims to beat back tough blood cancers in young patients
Disease control Recruiting nowThis early-phase study tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) for teens and young adults aged 12 to 30 whose T-cell acute lymphoblastic leukemia or lymphoma has returned or not responded to prior treatment. The main goal is to c…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 18, 2026 11:47 UTC
-
New immunotherapy combo aims to stop relapse in young blood cancer patients
Disease control Recruiting nowThis early-phase trial tests whether adding daratumumab (an immunotherapy drug) after a stem cell transplant can safely help control high-risk T-cell acute lymphoblastic leukemia or lymphoma in children, teens, and young adults up to age 39. About 30 participants will receive the…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: New York Medical College • Aim: Disease control
Last updated Jun 17, 2026 12:10 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD7 CAR T-cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and attack cancer cells. The …
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
New universal CAR t therapy targets tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immune cell therapy (called universal CAR T cells) for people with certain blood cancers, including T-cell leukemia and lymphoma. The therapy targets a protein called CD7 found on cancer cells. The study will check if the treatment is sa…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 17, 2026 12:06 UTC
-
New hope for tough blood cancers: drug combo trial opens
Disease control Recruiting nowThis study is for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma that has come back or not responded to treatment. Researchers are adding a new drug, capivasertib, to a standard chemotherapy and venetoclax regimen to see if it is safe and works better. T…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
Engineered donor cells take aim at tough T-Cell cancers
Disease control Recruiting nowThis early-phase study tests a new treatment for people with T-cell leukemia or lymphoma that has come back. The treatment uses specially trained immune cells from a healthy donor, designed to recognize and attack cancer cells carrying a marker called CD7. The goal is to see if t…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
Promising drug cocktail targets tough blood cancers in kids
Disease control Recruiting nowThis study tests whether a combination of three drugs—calaspargase pegol-mknl, decitabine, and venetoclax—can help control relapsed or treatment-resistant T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LLy) in patients aged 1 month to 21 years. T…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New hope for kids with tough leukemia: targeted drugs added to chemo
Disease control Recruiting nowThis study tests whether adding dasatinib or venetoclax to standard chemotherapy can help more children with T-cell acute lymphoblastic leukemia or lymphoma achieve a deep remission. About 100 children and young adults aged 1 to 18 will receive one of these targeted drugs alongsi…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New drug aimed at wiping out hidden leukemia cells after chemo
Disease control Recruiting nowThis study tests whether daratumumab can eliminate tiny amounts of leukemia that remain after chemotherapy in people with T-cell acute lymphoblastic leukemia (T-ALL). About 20 adults whose cancer has come back or not fully cleared will receive the drug. The goal is to see if it c…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Engineered cells take on tough blood cancer in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called OC-1, which uses a patient's own immune cells (T cells) that have been modified in a lab to recognize and attack a specific marker (CD1a) on cancer cells. The trial aims to see if this therapy is safe and can help shrink or elim…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: OneChain Immunotherapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Promising combo aims to boost remission in rare blood cancer
Disease control Recruiting nowThis study tests whether combining venetoclax with azacitidine can help people with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) achieve remission. About 28 participants aged 15 and older will receive the drug combination for up to two 21-day cycles. The main goal …
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 08, 2026 13:07 UTC
-
New screening trial aims to match kids with relapsed leukemia to targeted therapies
Knowledge-focused Recruiting nowThis study screens children and young adults up to age 22 whose leukemia has returned or is hard to treat. By testing their blood and bone marrow, doctors can identify specific genetic markers to match them with the most promising experimental treatments. The goal is to build a r…
Matched conditions: T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: PedAL BCU, LLC • Aim: Knowledge-focused
Last updated Jun 22, 2026 12:08 UTC